Send to

Choose Destination
Clin Biochem. 2015 Jun;48(9):562-8. doi: 10.1016/j.clinbiochem.2015.02.003. Epub 2015 Feb 16.

Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases.

Author information

Internal Medicine Department, State Medical University, Zaporozhye, Ukraine.
Centre for Chronic Disease Prevention and Management, College of Health and Biomedicine, Victoria University, St Albans, Australia.
Molecular and Cellular Therapeutics Department, Royal College of Surgeons in Ireland, Dublin, Ireland.
Department of Histology and Embryology, School of Medicine, University of Ljubljana, Ljubljana, Slovenia.
International Clinical Research Center, St. Anne's University Hospital, Masaryk University, Brno, Czech Republic. Electronic address:


Endothelial-derived microparticles (EMPs) are a novel biological marker of endothelium injury and vasomotion disorders that are involved in pathogenesis of cardiovascular, metabolic, and inflammatory diseases. Circulating levels of EMPs are thought to reflect a balance between cell stimulation, proliferation, apoptosis, and cell death. Increased EMPs may be defined in several cardiovascular diseases, such as stable and unstable coronary artery disease, acute and chronic heart failure, hypertension, arrhythmias, thromboembolism, asymptomatic atherosclerosis as well as renal failure, metabolic disorders (including type two diabetes mellitus, abdominal obesity, metabolic syndrome, insulin resistance) and dyslipidemia. This review highlights the controversial opinions regarding impact of circulating EMPs in major cardiovascular and metabolic diseases and summarizes the perspective implementation of the EMPs in risk stratification models.


Cardiovascular diseases; Endothelial-derived microparticles; Metabolic diseases; Risk stratification

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center